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Universidade de Évora - Escola de Ciências e Tecnologia
Mestrado Integrado em Medicina Veterinária
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da Escola de Ciências e Tecnologia:
Presidente | Rita Payan-Carreira (Universidade de Évora)
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Mesenchymal stem cells (MSCs) promote the regeneration of scarless tendon tissue after injury. 
Various sources have been described and used to obtain MSCs, adipose tissue and bone-marrow 
are one of the most used.   
A population of 49 horses, that suffered superficial digital flexor tendonitis or suspensory ligament 
desmitis and were treated either with the combination of stromal vascular fraction and platelet 
rich plasma, or with allogenic bone marrow derived MSCs, was analyzed retrospectively. The 
influence of different factors (age, breed, discipline, injury chronicity, treated structure and type of 
MSCs used) on the outcome of the therapy was evaluated. The re-injury rate observed on the 
total population was 4% six months after MSC therapy, and 17,8% after 12 months.  
The results obtained are similar to results obtained in other studies that evaluated the therapeutic 
effect of MSCs in horses, encouraging the use of these cells in the treatment of 
tendinoligamentous disorders.   
Keywords: Mesenchymal stem cell; equine; suspensory ligament; superficial digital flexor 








Tratamento intralesional com células estaminais mesenquimatosas em cavalos com 
desmite do ligamento suspensor e tendinite do tendão flexor superficial digital: um estudo 
retrospetivo. 
As células estaminais mesenquimatosas (MSCs) promovem regeneração de tecido tendinoso 
saudável após a lesão. Vários tecidos têm sido usados para obter MSCs, mas o tecido adiposo 
e a medula óssea têm sido os mais populares.  
Este estudo analisou retrospetivamente uma população de 49 cavalos, com tendinite do tendão 
flexor digital superficial ou desmite do ligamento suspensor, que foram tratados com uma 
combinação de fração estromal vascular com plasma rico em plaquetas, ou com células 
estaminais mesenquimatosas alogénicas derivadas de medula óssea, avaliando a influência de 
diversos fatores (idade, disciplina, raça, cronicidade da lesão, estrutura tratada e tipo de células 
estaminais usadas) sobre o resultado da terapia. A taxa de lesões recidivas na população em 
estudo era de 4% 6 meses depois do tratamento com células estaminais, e 17,8% após 12 
meses. 
Os resultados obtidos neste estudo são semelhantes a outros estudos que avaliaram o mesmo 
tipo de terapias. 
Palavras-chave: Células estaminais mesenquimatosas; equino; ligamento suspensor; tendão 
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For a long time, tendon and ligament injuries have been one of the most devastating injuries for 
any athlete, the equine athlete being no exception. The intrinsic characteristics of tendon and 
ligament tissues do not allow for a complete regeneration of injured tissue, what means that once 
an injury has occurred the probability that the same injury will return after apparent healing is high. 
Since the beginning of this century investigators have been busy in trying to obtain a therapy that 
would allow for a better regeneration of tendon tissue. One of the therapies that has been 
successful in return equine athletes to their performance levels, after injury, is mesenchymal stem 
cell therapy. The following literature review attempts to gather and deliver to the reader a 
comprehensive vision about MSC therapy and its impact on equine veterinary medicine. To add 
information to further advances in MSC therapy, the literature review is followed by a retrospective 
study that aims to observe the effects that two different MSC sources have on superficial digital 
flexor tendonitis and suspensory ligament desmitis. The influence of discipline, breed, age, and 





1 Tendon/Ligament anatomy & physiology  
1.1 Clinical anatomy 
1.1.1 Suspensory ligament 
The suspensory apparatus has three major components: the suspensory ligament (SL), the 
proximal sesamoidean bones (PSB) and the four distal sesamoidean ligaments. The main 
component of this apparatus is the SL, a strong tendinous band that originates from the palmar 
surface of the third metacarpal bone (McIII), with some fibres arising from the axial aspect of the 
fourth metacarpal bone (McIV) (Nagy et al., 2012), and a minority of these fibres coming from the 
deep carpal ligament (Budras et al., 2011). The proximal and mid-body regions of the SL run 
between the axial aspects of McII and McIV, and palmar to McIII (Denoix, 1994). The SL 
bifurcates into two branches in the mid-metacarpal region, the lateral and the medial suspensory 
ligament branches. These branches insert in the abaxial surface of the apex of the PSBs, making 
a wide attachment along this surface and joining the origin of the ipsilateral collateral 
sesamoidean ligament (Fails, 2020). From the distal surface of the PSB a thin extensor branch 
leaves, running forward in an oblique direction across the proximal phalanx, merging with the 
common digital extensor on its dorsoproximal surface. The suspensory apparatus (Figure 1 and 
2)  continues in a distal direction through the distal sesamoidean ligaments: the oblique 
sesamoidean ligament (OSL), the short sesamoidean ligament (SsL), the straight sesamoidean 
ligament (SSL) and the cruciate sesamoidean ligament (CSL) (S. J. Dyson et al., 1995). All these 
ligaments originate from the base of the PSBs and the proximal scutum, as well as the palmar 
ligament (Denoix, 1994; Budras et al., 2011). The SSL inserts on to the palmar proximal aspect 
of the middle phalanx via the scutum medium. The medial and lateral OSL converge to insert on 
the proximal surface of the middle phalanx. The CSL constitutes the palmar border of the distal 
palmar synovial recess of the metacarpophalangeal joint. Finally, the SsLs have a diminutive body 
and insert on the palmar proximal 
surface of the proximal phalanx, 
because of their size and location 
they are difficult to distinguish 
from the deep portion of the OSL 





Figure 1 - Caudal view of the distal 






When comparing the front limb and hind limb SL, important differences can be identified, for 
example the front limb SL has a rectangular and strong structure, that measures between 20 and 
25 centimetres, while the hind limb SL is a thinner and rounder ligament, that measures 25 to 30 
centimetres (Denoix, 1994). In the front limb the SL can be observed as a bilobed structure, right 
from the level of the origin. Usually the medial lobe is thinner and wider than the lateral lobe. As 
the ligament goes distally the lobes join to form an oval shaped structure, this occurs normally 
five to six centimetres distal to the carpometacarpal joint. Until the bifurcation this oval shape is 
maintained (Werpy et al., 2012).  
In the hindlimb, the attachment to the plantar tubercle of the first, third and fourth tarsal bones is 
less prominent than in the front limb (Denoix, 1994). At the level of the proximal McIII, the SL 
starts off with a triangular shape. This triangle is thinner medially than it is laterally. Along the 
metacarpal groove the SL becomes gradually heart shaped, then rounded and finally oval, until 
the bifurcation of the SL branches. The apex of the triangular shape, as well as the heart shape, 
is directed in the plantar lateral direction (Werpy et al., 2012).  
 
There are two main arteries that supply the front limb SL with blood, these are the lateral and 
medial metacarpal arteries, that descend at the palmar aspect of McIII, and originate in the deep 
palmar arch, which can be found close to the carpometacarpal joint. This arch is the result of the 
junction of the radial artery (medial) and the ulnar collateral artery (lateral) (Denoix, 1994; Budras 
et al., 2011; Werpy et al., 2012). The venous drainage of the SL is obtained through a satellite 
venous deep arch, between the medial and lateral metacarpal veins, that is both on the palmar 
and the dorsal aspects of the ligament. This arch is in turn drained by the ulnar vein (lateral) and 
the cephalic vein (medial) (Werpy et al., 2012). 
In the front limb the SL receives innervation from a deep branch of the plantar branch of the ulnar 
nerve. This deep branch originates in the region of the distal carpus. These branches receive 
nerve fibres from the median nerve (Muylle et al., 1998).  
In the hindlimb the medial and lateral plantar arteries are responsible for the blood supply. These 
arteries derive from the tarsal artery that perforates the tarsal canal after it branches of the dorsal 
pedal artery in the region of the dorsolateral hock. The venous return is obtained by the second 
plantar metatarsal vein, that joins the cranial tibial vein after it perforates the tarsal canal (Denoix, 
1994; Budras et al., 2011; Werpy et al., 2012) 
 
1.1.2 Superficial digital flexor tendon 
The superficial digital flexor tendon (SDFT), together with its accessory ligament (ALSDFT), is 
one of the most important anatomo-functional components of the equine limb, along with the deep 
digital flexor tendon (DDFT) and its accessory ligament (ALDDFT), and the previously described 
suspensory apparatus (Denoix, 1994). The SDFT arises from the superficial digital flexor muscle, 





proximal portion of the accessory 
carpal bone. In the carpal region, 
proximal to the antebrachiocarpal 
joint, the ALSDFT, also called the 
superior check-ligament, joins the 
SDFT from a dorsomedial and 
oblique direction, originating from 
the dorsomedial aspect of the 
radius. As it runs distally, the 
SDFT passes through the carpal 
canal as a round shaped tendon, 
that in the proximal metacarpus 
flattens and becomes half-moon 
shaped, with a sharp lateral margin 
and a rounded medial border. It maintains its shape along the metacarpus until the distal 
metacarpal region is reached, where it turns into a symmetrical and wide tendon, becoming 
thinner in a dorsopalmar direction and extending into a fibrous ring, called the manica flexoria, 
that encircles the DDFT (Roger K W Smith, 2007). Distal to the PSBs, the SDFT continues as a 
thin and wide structure, until it branches at the level of the mid proximal phalanx. These branches 
thicken distally and end between the palmar ligaments of the proximal interphalangeal joint, on 
the proximopalmar aspect of the middle phalanx, through the middle scutum (Denoix, 1994; Roger 
K W Smith, 2007; Budras et al., 2011).  
 
The SDFT is supplied with blood by various arteries. One of these is a “nutrient artery”, that 
originates from the median artery, along the ALSDFT and enters the tendon in the 
musculotendinous junction. The proper digital artery also provides blood to the SDFT through an 
arterial branch that branches off near the proximal margin of the palmar annular ligament. 
Together these arteries supply the intratendinous arterial network and two arteries that run on 
each side of the SDFT (Denoix, 1994). 
 
1.2 Structure and composition of tendon and ligament 
Tendon is an elaborate structure that is the product of a complex organization between tendon 
cells (tenocytes), proteins of the extracellular matrix, blood vessels, lymphatic vessels and nerves 
(Birch et al., 2013). This complex organization, together with a specialized molecular composition, 
results in a high strength structure, capable of resisting profound uni-directional forces 
(Chavaunne Thandiwe Thorpe, 2010). The extracellular matrix is composed of collagen (mainly 
type I), non-collagenous proteins, and a high water content (65% (Kümmerle et al., 2019)), which 
is important to ensure the elastic properties of the tendon tissue (Birch et al., 2013).  






Non collagenous proteins are mainly proteoglycans and glycoproteins. Proteoglycans can be 
subdivided in large proteoglycans and small leucine rich proteoglycans. An important glycoprotein 
is the cartilage oligomeric matrix protein (COMP), a protein that has a structural role in tendon 
development, as it has been shown in vitro that COMP can accelerate collagen fibrillogenesis. It 
accumulates during growth, reaching its highest concentration at maturity. As the animal ages 
COMP concentration decreases, explaining partially the reduced healing ability of older tendons 
(Halász et al., 2007; Birch et al., 2013). 
 
Proper maintainance of the extracellular matrix is realized by a small population of fibroblast like 
cells, better known as tenocytes (Kümmerle et al., 2019). They produce tropocollagen, that self 
assembles into fibrils, in a parallel regular organization, along the tensional axis of the tendon. 
These fibrils are the start of the basic structure of the tendon, and they organize into collagen 
fibres, that are surrounded by endotendon to form fibre bundles called fascicles. The whole 
tendon is surrounded by a fine layer of connective tissue, called the epitendon (Birch et al., 2013). 
This hierarchical structure can be observed in Figure three, which illustrates all the main 
components of collagen 
organization within the 
tendon. A feature, specific for 
tendons is seen at the 
microscopic level, where 
collagen fibrils adopt a 
straight organized pattern, 
oriented along the direction of 
the main stress load of that 
tendon. This is in contrast to 
the right-handed helical path 
followed by collagen fibrils in 
tissues like the skin (Birch et 
al., 2013; Franchi et al., 2010). 
However, collagen fibrils in some regions of the tendon show fibrillar crimps, that are formed as 
the fibrils first twist leftwards, changing their plane of running, and then bend sharply also 
changing the direction of coursing. This functions as a biological hinge, that opens when tensional 
load is applied on the tendon and recoiling when the load is removed (Franchi et al., 2010; Birch 
et al., 2013).  
 
Looking at the tenocytes we can distinguish three types, according to nuclear morphology, 
localization, and presence in either juvenile or adult tissues (Banes et al., 1988; Roger K.W. Smith 
et al., 2008). Type I tenocytes have flattened, cigar shaped nuclei. They are the “satellite” 
tenocytes that lie between the collagen fibres. Type II tenocytes are the active type. They have a 






rounded nucleus and can be found in linear groupings between collagen fibres. Type III collagen 
fibres are chondrocyte like and are found in regions of the tendon that are submitted to the biggest 
compressive forces (Goodship et al., 1994; Stanley et al., 2008). The true extension of the 
synthetic activity of tenocytes is unknown, but it is known that the turnover of non-collagenous 
components is higher than the collagenous components, suggesting that the plumper cells, 
present in the endotendon, are more active than the cells present between the collagen fibers, 
with elongated nucleus (Chavaunne T. Thorpe et al., 2010; Birch et al., 2013).  
 
The SL is a modified muscle with tendinous characteristics. The main difference when compared 
with the SDFT and other tendons is the percentage of present muscle fibers (Pimenta, 2018) 
which can reach percentages between 2% and 11%, explaining its anatomical identification as 
“the interosseus muscle” (Denoix, 1994). The main muscle fibres that compose the ligament are 
type I fibres, which are slow twitch fibres. The muscle portion of the SL likely contributes to 
forelimb stability and elastic energy storage during locomotion (Soffler et al., 2006). 
1.3 Functional role of tendons and ligaments  
Tendons and ligaments have a 
primary role of connecting muscle to 
bone and bone to bone, respectively. 
But the SDFT and the SL are 
specialized structures, with 
specialized roles. They are the 
product of an evolutionary 
adaptation that allowed the horse to 
become one of the fastest runners 
on the planet. This anatomical 
adaptation to reach faster speeds is 
expressed by a simplified distal 
extremity structure, with reduction of 
the muscle mass in the distal limb, 
development of accessory ligaments 
to strengthen the function of the 
limbs, both in the active and passive 
phase of locomotion, and development 
of a specialized tendon and ligament apparatus that can withstand the forces being exerted on 
the distal limb. The function of the digital flexor tendons and the SL has phylogenetically evolved 
into a biological spring, which “winds up” as it bears the weight of the fully supported limb, 
preventing the hyperextension of the metacarpophalangeal joint (Denoix, 1994), store the energy 
that is generated, and release the energy once the limb is protracted (Wilson et al., 2001) (Figure 
Figure 4 - Anatomic structure vs bio-mechanic structure of the 





4). It has been shown that this mechanism buffers up to 36% of the mechanical work during gallop, 
and 40% during the transition from walk to trot (Biewener, 1998). The accessory ligaments further 
reduce the energy spent by muscle work by providing a direct bone-to-bone tendinous connection 
when the limb is bearing the full weight, as they attach the tendon directly to the bone (Birch et 
al., 2013).  The SDFT has an added function as it flexes the digit during the swing phase of 
locomotion (Batson et al., 2003).  
1.4 Tendon biomechanics  
During locomotion, the flexor tendons are subjected to tension during the weight bearing phase, 
stretching and stressing the tendon tissue. It allows the flexor tendons to show their main physical 
properties: high tensile strength, flexibility, and elasticity (Goodship et al., 1994). 
A diagram that illustrates the relationship between the force applied per unit of area (stress) and 
percentage of elongation (strain), shows how the tendon behaves according to the tension applied 
on it. There are four distinct regions in the diagram: 1) the start episode, called “the toe phase”, 
is characterized by a non-linear stretch of the tendon, that does not comply with Hooke’s law, a 
common feature in collagenous structures (Goodship et al., 1994). This means that although a 
relatively small load is applied, the tendon tissue shows great extension. The extension occurs 
due to sliding of the fascicles. The toe phase is associated with the elimination of the crimp pattern 
in the fascicles because of this sliding mechanism (Chavaunne et al., 2012). The crimp length 
and angle is still recoverable in the toe phase, if the load is removed, meaning that the tendon is 
still elastically recoverable (Goodship et al., 1994); 2) When the load applied to the tendon further 
increases, the resistance to further elongation of the tissue also increases (i.e. increase in 
stiffness). Here we see a linear relationship between stress and strain. It is in this phase that the 
structural property of stiffness is determined (load divided by deformation) (Kümmerle et al., 
2019). The elongation mechanism occurs by elongation of the collagen fibrils, a step further from 
the elongation of the fascicle fibre elongation in the toe region. The fibrillar crimp is straightened 
out and there is sliding of fibrils and fibers relatively to one another; 3) A continued increase in 
strain applied to the tendon will lead to irreversible lengthening of the tendon, the consequence 
of slippage of collagen fibrils, fibers or fascicles (Birch et al., 2013), and covalent crosslink rupture 
(Kümmerle et al., 2019). This region of the curve is called the yield point and is characterized by 
a reduction in stiffness of the tendon. Strains of 12% to 20% have shown to be responsible for 
these effects on the tendon (Stephens et al., 1989); 4) The final region of the curve represents 
rupture of the tendon, when the stress-strain curve fails (Birch et al., 2013) the collagen cross-
links or fibrils rupture (Roger K.W. Smith, 2010). As determined in vitro, these events occur at 
strains around 25% (Birch, 2007).  
Studies have shown that the strain applied to the equine SDFT during gallop can reach values as 
high as 16% (Stephens et al., 1989), which shows how close physiological and  failure strains 
approach each other during maximal exercise, only allowing for a narrow biomechanical safety 





explanation for the high incidence of tendon injury seen in the horse, and especially the athletic 
horse.  
Equine tendons are highly effective spring 
mechanisms, with low energy dissipation, 
absorbing up to 93% of the muscular work 
performed in the limb movement through an 
elastic recoil. The remainder of the energy is 
dissipated as heat (Alexander, 2002). This 
energy dissipation can be classified as 
hysteresis, the result of the difference between 
the stress/strain ratio of the loaded tendon 
compared with the unloaded tendon (Roger 
K.W. Smith et al., 2008) (Figure 5). The heat 
produced by energy dissipation rises the 
temperature within the tendon core when the 
tendon is repeatedly put under tension, as in the 
exercising horse (Kümmerle et al., 2019). It is 
hypothesised that this is one of the main causes 
of tendon injury in the athletic horse (Wilson 
1994).  
 
When comparing the SDFT to a tendon with less 
weight supporting tasks, like the CDET, a 
positional tendon (Kümmerle et al., 2019), the 
SDFT has a higher CSA, and has a higher 
structural stiffness, which means that it has a 
higher failure load, as well as a lower mean elastic modulus (Roger K.W. Smith, 2010). These 
properties allow the SDFT to store a greater amount of elastic energy in comparison to the CDET. 
Studies have shown that the SL has comparable characteristics to the SDFT and shares a role in 
storing elastic energy during locomotion. The SDFT and the SL have a lower elastic modulus than 
the CDET, which means that they are less rigid structures, returning more elastic energy during 
locomotion (Birch, 2007; Alexander, 2002). The SDFT and the SL have a very similar extracellular 
matrix composition and configuration: both contain high COMP levels and a combination of small 
and large collagen fibrils. In contrast, the CDET and the DDFT, tendons with different roles in the 
limb, have lower levels of COMP and mostly large collagen fibrils (Kümmerle et al., 2019). 
1.5 Tendon injury and repair  
The most common orthopaedic injury in equine athletes is strain induced tendon and ligament 
injury (Birch et al., 2013). The type of injury can be related with certain disciplines, for example 
Figure 5 - A: stress-strain curve; B: hysteresis and 
conditioning. Hysteresis is shown as the difference 
between the loading and unloading curves. 
Conditioning is the result of the viscoelastic 
properties of the tendon. As the tendon is 
repeatedly loaded and unloaded it becomes more 
elastic, shifting the stress-strain curve to the right 





show-jumping horses have a greater prevalence of SDFT and DDFT injuries, while dressage 
horses have more hindlimb SL injuries (Murray et al., 2006). The prevalence of flexor tendon and 
SL injuries on UK racetracks (flat racing and National Hunt racing), in 1997, 1998 and 1999, 
represented 46% of all reported limb injuries, and subsequent clinical evaluation revealed that 
these injuries where more common among older horses (Williams et al., 2001). Another study 
gathered information of 1223 horses, that spent 9466 months at risk of injury, and revealed that 
the SDFT and SL injury rate was accountable for almost two injuries per 100 months of training. 
Approximately 89% were SDFT injuries, and the remaining injuries were SL injuries (Ely et al., 
2009). 
Tendinopathies occur due to extrinsic 
or intrinsic factors that negatively affect 
the tendon structure and tissue. 
Extrinsic factors include percutaneous 
trauma, while intrinsic factors are 
mainly triggered by the strain applied 
to the tendon (Kümmerle et al., 2019). 
Injuries with an intrinsic origin can 
occur in two ways, either through a 
sudden overload of the tendon, or 
through the progressive degeneration 
of the tendon tissue (Birch et al., 
2013). In most cases tendon 
degeneration precedes any clinical 
injury, progressively weakening the 
structure, eventually leading to clinical 
lesions (R. K. Smith et al., 2002; R. K. 
Smith et al., 1999). Several studies 
have established that degeneration 
effectively precedes most clinical injuries (R. K. Smith et al., 2002; R. K. Smith et al., 1999). 
The degeneration of tendon tissue is usually attributed to cyclical over loading, which leads to 
cumulative fatigue and microdamage (Kümmerle et al., 2019). It is known that tendon 
degeneration is characterized macroscopically by a change in coloration of the tendon core, along 
with changes in the matrix itself, such as elevated levels of GAGs, collagen type III fibres and also 
an increase in cellularity, as well as decreased collagen linked fluorescence, a marker of matrix 
age (Birch et al., 1998) (Figure 6). These changes that come along with tendon degeneration 
indicate an elevated matrix turnover speed, that can be the result of a failure to establish a good 
healing response or an inability of cellular response (Thorpe et al., 2010) by the resident cell 
population (Kümmerle et al., 2019). High speed locomotion, such as canter and gallop, leads to 
Figure 6 - Ultrasonographic images showing a core lesion in 
the SDFT, (A) transverse image, (B) longitudinal image. (C) 
Macroscopic appearance of a core lesion during healing 
(arrow). (D) Histologic appearance showing angiogenic 
response (arrow), cellular infiltration, and disorganized matrix 





high frequency and powerful repetitive strain power imposed on the soft tissues of the palmar 
surface of the distal limb, mainly the SDFT and the SL (Kümmerle et al., 2019; Thorpe et al., 
2010). These important strain forces can result in localised physical damage to the tendon matrix, 
rupturing of fibres and crosslinks, affecting matrix proteins, and as a consequence, induce 
production of proteolytic enzymes, such as MMP-1 (Arnoczky et al., 2007; Lavagnino et al., 2006), 
which on their turn induce secondary damage. The older the animal is, the more pronounced the 
effects of this damage are (Dudhia et al., 2007). Although this damage is localised, it is likely to 
alter cell matrix interactions (Arnoczky et al., 2008) and accumulate more damage, as the 
tenocytes are unable to achieve a complete repair of the microdamage (C. T. Thorpe et al., 2010). 
The primary effects of physical damage and the secondary damage by proteolytic enzymes can 
generate cleaved matrix proteins, that can also induce further damage to the matrix. This chain 
of events can result in a vicious circle of matrix degeneration, induced by exercise (Dakin et al., 
2014; Johnson et al., 2004). Another mechanism that can result from primary physically induced 
microdamage is the “reduction of loading tenocytes” (Kümmerle et al., 2019). When there is 
microdamage to the tendon tissue the damaged fibrils are unloaded (Lavagnino et al., 2006) and 
as a consequence are shielded from stress. It has been shown in vitro that stress deprivation 
results in elevation of proteolytic enzymes, such as collagenase MMP-13, as well as changes in 
cell morphology, pericellular environment (Arnoczky et al., 2008) and upregulation of protein 
synthesis in tendon cells (Egerbacher et al., 2006). The under stimulated tenocytes react 
differently to mechanical stimulus, being unable to respond normally to microdamage (Thorpe et 
al., 2010).  
Temperature changes in the tendon can also have a negative effect on the tendon matrix. As 
referred previously, tendons store energy during locomotion, returning most of it as elastic energy 
to the movement of the limb, but about 7% of this energy is released as heat, elevating 
temperatures of the tendon core up to 45 degrees Celsius (Goodship et al., 1994). Although it 
has been shown in vitro that tenocytes of the SDFT can resist temperatures of as much as 48 
degrees Celsius (Birch et al., 1997), it may be possible that, in situ, the ability of the cells to 
communicate via their gap junctions renders the tendon cells more susceptible to heat (Burrows 
et al., 2003). Other studies have shown an increase in pro-inflammatory cytokines when equine 
tenocytes where subjected to temperatures above 45 degrees Celsius (Hosaka et al., 2006).  
SDFT injury may also be linked with fatigue of the deep digital flexor muscle. This muscle is rich 
in fast twitch muscle fibres, making it more susceptible to fatigue (Takahashi et al., 2014; Valberg, 
2008). The DDFT acts to stabilize the metacarpophalangeal joint during locomotion, impeding it 
from hyperextending, but as the muscle fatigues this stabilization decreases, allowing for an 
increase in extension of the metacarpophalangeal joint, and as a consequence the associated 





As previously mentioned, weight bearing tendons operate at their functional limits during high 
speed exercise (Kümmerle et al., 2019). Because of this, even small changes in the structural 
integrity of the tendon tissue, can result in irreversible damage, through physical disruption of the 
tendon matrix (Roger K.W. Smith, 2010). This disruption can vary from fibrillar slippage to 
complete separation of tendon tissues, which on its turn is expressed by different degrees of 
clinical injury. When this occurs, the organism tries to repair the damage in three phases:  
1) immediately after the disruption of the tendon matrix an acute inflammatory phase starts off, 
which usually lasts for a few days. The ultimate onset is an intra-tendinous haemorrhage, followed 
by infiltration of the injury site by neutrophils, macrophages and monocytes, and subsequent 
release of proteolytic enzymes. Also blood platelets infiltrate the injury site and release growth 
factors and endothelial chemo-attractants (Thomopoulos et al., 2015; Voleti et al.,  2012). 
Macrophages remove cellular debris, while growth factors recruit tenocytes to the wounded area 
and stimulate them to proliferate (Voleti et al., 2012).The inflammatory reaction is designed to 
remove damaged tendon cells, but it can exceed its effects, further damaging the tendon (Smith, 
2010). It has been shown that the modulation of inflammation, through macrophage depletion, in 
the early stages of inflammation after tendon reconstruction resulted in improved healing (Hays 
et al., 2008). Macrophages have a dual role, as they induce and resolve inflammation, but also 
facilitate and moderate tendon healing (Thomopoulos et al., 2015). It is known that macrophages 
can behave abnormally, inducing fibrosis, and diminishing tendon structure quality (Nichols et al.,  
2019). Keeping in mind reported results of studies looking into the role of inflammation and 
immune response in tendon healing and fibrosis, it is important to develop therapies that will 
moderate this first inflammatory phase and immune reaction, rather than invest in therapies that 
completely block the inflammatory chain (Nichols et al., 2019). 
2) The second phase is the fibroblastic phase, also called the subacute phase, and is 
characterized by strong synthetic activity orchestrated by macrophages and tenocytes 
(Thomopoulos et al., 2015). They induce a profuse angiogenic response, along with fibroblast 
accumulation (Birch et al., 2013). These fibroblasts come from extrinsic and intrinsic sources 
(Juneja et al., 2013) and are different from normal tenocytes, being responsible for the formation 
of scar tissue, which is also different from normal tendon tissue. It has a higher collagen type III 
content, is more hydrated, and has more GAGs (Nichols et al., 2019; Smith et al., 2013). The 
temporary matrix of collagen type III provides a scaffold for the migration of subsequently recruited 
cells into the wounded area (Nichols et al., 2019).  
3) The reparative phase begins one to two months after the onset of the injury and merges with 
the remodelling phase (Thomopoulos et al., 2015). During this phase there is a gradual 
transformation of collagen type III into collagen type I, as granulation tissue matures into scar 
tissue (Nichols et al., 2019; Williams et al., 1980). This transformation is incomplete, because 





collagen type I matrix (Nichols et al., 2019). The presence of extrinsic cells is also believed to be 
a cause for incomplete transformation. Myofibroblastic cells have been detected in scar tissue of 
naturally occurring superficial digital flexor tendinopathy (Williams et al., 1980), and a prolonged 
activity of this type of cells is linked with fibrosis in organs like kidneys and lungs (Meran et al., 
2011; Phan, 2002). The new collagen I fibres that are indeed produced, become thicker, the 
crosslinks that bind them increase in number, and fibre alignment improves. Within and around 
the tendon there are deposited large amounts of fibrous tissue, enlarging the whole tendon, and 
making it a stiffer structure (Kümmerle et al., 2019). The increase in structural stiffness and 
persistently deficient structural organization and composition of the matrix has a negative impact 
on the biomechanics of the tendon. It reduces the efficiency of the spring mechanism, 
compromising the performance of the horse and adding the risk of re-injury (Crevier-Denoix et al., 
2010).  
The cells that are recruited for repair of damaged tendon come from extrinsic cell populations, 
originating in the peripheral circulation, as well as neighbouring tissues like the paratendon and 
tendon sheath. Intrinsic cell populations also contribute to the cellular infiltrate of the lesion. They 
are derived from tendon parenchyma, epitendon and endotendon (Nichols et al., 2019). It is 
important to know the way these two cell sources impact tendon healing. Extrinsic cells promote 
the formation of scar tissue and adhesions (Nichols et al., 2019), while a cell population dominated 
by intrinsic cells results in a scarless regenerated tissue (Beredjiklian et al., 2003), as shown in 
foetal tendon healing, where intrinsic healing dominates over extrinsic healing.  
 
The various factors that influence tendon healing have to be well known in order to obtain a 
therapy for tendon injury that fully regenerates original tendon tissue, restoring its normal 
biomechanical and functional properties.  
2 Current orthopaedic therapies 
A brief description of the current therapies that can be applied to SDFT tendonitis and SL desmitis 
will be provided in this section. Only medical treatment and rehabilitation methods will be 
described as surgical therapies are beyond the scope of this thesis.  
 
Medical treatment of tendon and ligament injury should start as soon as possible after the lesion 
occurs in order to prevent overzealous expression of acute swelling and inflammation (Eggleston 
et al., 2020).  
 
This especially applies for suspensory ligament desmitis. The body of this ligament is confined in 
a narrow canal between McII, McIII and McIV. The rapid resolution of swelling is crucial to prevent 






2.1 Medical management  
Non-steroidal anti-inflammatory drugs are recommended for the treatment of acute stage injury. 
NSAIDs work through the inhibition of cyclooxygenase (COX) enzymes, promoting analgesic and 
anti-inflammatory effects (Bentz, 2015). COX enzymes are involved in the conversion of 
arachidonic acid into important elements of inflammation, prostaglandins and thromboxanes 
(Baxter, 2011), so their inhibition will prevent the synthesis of these inflammatory factors.  
Different NSAIDs seem to behave differently depending on the injured system. While flunixin 
meglumine is the strongest NSAID to alleviate visceral pain in the horse with colic, 
phenylbutazone is considered the best NSAID specifically for musculoskeletal lesions (Kirker-
Head et al., 2013).  
Beside systemic administration of NSAIDs, also topical application of NSAIDs can be considered, 
such as diclofenac liposomal cream. When applied, this drug penetrates the skin and has direct 
local anti-inflammatory effects through COX enzyme inhibition and analgesic effects through its 
capacity to block sodium channels of noci-receptive afferent fibres (Nair et al., 2010). 
 
Corticosteroids are an option during the first 24 to 48h after lesion induction, however beyond this 
time window their use is not recommended as they can inhibit fibroplasia and impede the normal 
healing of the tendon as a consequence (Kümmerle et al., 2019). There are scientific sources that 
advise against the topical use of perilesional dexamethasone during the acute phase, as it may 
delay collagen formation. Other sources indicate that the histological appearance of equine 
tendon injected with corticosteroids resembles the histological image of tendinopathy (McIlwraith, 
2010). Depot corticosteroids like methylprednisolone should not be administered directly in the 
tendon or ligament, because of the risk of dystrophic mineralization and tissue necrosis, caused 
by the carrier of the drug ( Smith, 2007). 
 
Polysulfated glycosaminoglycan (PSGAG) can be considered as a soft-tissue anti-inflammatory 
agent (Kümmerle et al., 2019) because of its inhibitory effect on enzymes such as collagenases 
and metalloproteinases, as well as inhibiting macrophage activation and promoting a suppression  
of inflammation (Moraes et al., 2009). These properties make it an adequate product to be used 
in the acute stage of injury (Dowling et al., 2000). Although it has no effect on the synthesis of 
fibroblasts (Kümmerle et al., 2019) PSGAG has an effect on the metabolism of tenocytes and 
fibroblasts, which consequently influences the production of collagen and non-collagen proteins 
(Moraes et al., 2009). Despite these known characteristics of PSGAGs, a long-term clinical study 
has found no difference in the recurrent injury rate of horses whose tendons were treated with 
systemic or intralesional PSGAGs, compared to horses that were treated with controlled exercise 
alone (Dyson, 2010; Dyson, 1997).  
A recommended treatment plan with PSGAGs consists of the intramuscular administration of 






Hyaluronan is a natural component of tendon matrix. It has a direct influence on the formation of 
collagen fibrils and their aggregation, as it stimulates synthesis of collagen type I (Ross et al., 
2011). When administered intrathecally hyaluronan may diminish the formation of adhesions 
during tendon repair, along with reducing the inflammatory cell infiltrate as well as the intra-
tendinous haemorrhage (Kümmerle et al., 2019).  
2.2 Physical Therapies  
Before medical treatment is begun there are basic procedures that can diminish the progress of 
inflammation and further damage to the tendon. Cold therapy can be installed in the acute phase 
of the inflammation, as it has an immediate anti-inflammatory and analgesic effect. Cold 
temperatures promote vasoconstriction, reduce both enzymatic activity and synthesis of 
inflammatory mediators, and diminishes nerve conduction (Petrov, Hoogmoed, 2003).  
 
Bandaging is useful to reduce the oedema that forms in the surrounding tissue following tendon 
injury (C. Gillis, 2011). It may also assist healing as stimulation of mechanoreceptors occurs 
(Baxter, 2011). 
 
Foot conformation and shoeing can help diminish the strains applied to the affected tendon. To 
reduce strain on the SL and SDFT it is important to have a straight pastern/hoof axis, putting the 
metacarpophalangeal joint in a normal position. Elevation of the heel is contraindicated as it 
increases strains on the SL. It is best to shorten the toe and increase the hoof angle (Dyson et 
al., 2010). If the horse doesn’t have enough support from his foot shape, an egg bar shoe can be 
used (Gillis, 2011). It can also be helpful to raise the toe or apply a shoe with a wider width in the 
toe region, impeding the toe from sinking too much in soft terrain, this way transferring the load 
from the SL and SDFT to the DDFT (Kümmerle et al., 2019). 
  
Several different physical techniques for the treatment of tendon disorders have been developed. 
Modalities such as extracorporeal shockwave therapy and laser therapy claim to stimulate the 
regeneration process, through reduction of inflammation and swelling, increase in blood 
circulation and alleviation of pain (Bergh, 2011). 
 
Extracorporeal shockwave therapy works through the transmission of shockwaves into the tendon 
tissue. The exact effect that these waves produce is unclear, but it is most likely that they induce 
analgesia and decreasing nerve conduction properties in sensory nerves (Bolt et al., 2004). It has 
been noticed that in normal tissue the shockwaves can be deleterious, but in diseased tendon the 
induction of tendon matrix disorganization can be a stimulus for repair in chronic injuries (Bosch 
et al., 2007). A study investigating the use of extracorporeal shockwave as a therapy for chronic 
SL desmopathy concluded that 41% of the treated patients resumed full work six months after the 





showed a 13% return to full work in the same time frame when the patients were treated 
conservatively (Dyson, 1994).  
Low-power laser therapy has been shown to promote cellular metabolism, besides enhancing 
fibroblast proliferation and collagen synthesis in vitro (Henninger, 1994).  
The physiological effects of laser therapy include anti-inflammatory effects, more organized 
fibroblasts, increased cellularity, increased collagen formation, vasodilation, increased 
concentration of capillaries, DNA synthesis, RNA production and pain reduction through the 
influence of the pain gate and nerve velocity (Bergh, 2011). 
The variety in treatment protocols of laser therapy makes it difficult to show consensual results 
between different studies (Schindl et al., 2000). There are studies that report positive results when 
infrared laser was applied in tendonitis cases. While other investigations suggest negative results 
regarding tendon healing in horses (Bergh, 2011). The ambiguous results that are associated 
with low-power laser may be related to the insufficient depth of penetration (Ryan et al., 2007). In 
recent years veterinary medicine has been adopting high-power laser therapy from human 
medicine, hoping for more consistent results in the treatment of soft-tissue orthopaedic injuries. 
A recent study with 150 horses showed that this therapy was both safe and efficacious, with 
significant improvement in lameness scores and low re-injury rates (Pluim et al., 2018).  
 
Stall confinement is mandatory during the rehabilitation phase. It is important to control the 
exercise the horses undergo, as excessive exercise can further damage the tendon and impede 
its normal healing. Box rest combined with controlled walking exercise for two months is normally 
recommended. Exercise helps resolve residual inflammation, maintain gliding function, and 
promote optimal collagen remodelling (Gillis, 1997; Smith, 2007). During this exercise program it 
is important to make serial ultrasonographic evaluations to control the tendon healing and 
eventually detect any setbacks (Eggleston, 2020) .  
3 Regenerative medicine 
None of the accepted treatment methods has been consistently better than any other for the long-
term return to athletic activity without re-injury. After tendon injury, extensive scar tissue replaces 
the original tendon tissue, which means that the new tendon structure is architecturally and 
functionally inferior to the original structure. Regenerative medicine aims to overcome this 
obstacle in returning full normal function to the tendon, while also diminishing the risk of re-injury. 
The ideal regenerative therapy “avoids the formation of excessive fibrous tissue and is able to 
regenerate normal tendon matrix”. It tries to replicate the events that occur during tissue 
development, allowing spatial and temporal interaction between three main factors: 1) scaffold 2) 
growth factors 3) cells (Smith, 2008; Smith, 2020). These three factors can be applied alone but 
ideally in combination with each other, along with mechanical stimulation, that is delivered through 






Platelet rich plasma has been emerging in recent years as a promising treatment for tendon and 
ligament injuries. It is an autologous whole blood product, that contains two to four times the 
concentration of platelets that are present in normal venous blood (Fortier, 2010; Smith, 2007). 
Platelets are one of the main sources of growth factors and bioactive proteins such as cytokines 
and chemokines. When delivered at the injury site, platelets contact the exposed basement 
membrane, which stimulates the platelets to aggregate and degranulate, releasing the anabolic 
bioactive substances, that promote tissue repair, regulate inflammation, and stimulate recruitment 
of stem cells (Fortier, 2010). The growth factors released by platelets, after the degranulation of 
alpha-granules, include platelet-derived growth factor (PDGF), transforming growth factor beta 
(TGF-beta), vascular endothelial growth factor (VEGF), and insulin like growth factor one (IGF 1) 
(Koch et al., 2019). All these growth factors are protein signalling molecules, that regulate cellular 
metabolism, stimulating cell proliferation, increasing cellular matrix synthesis, promoting vascular 
in-growth, while also downregulating catabolic matrix degrading cytokines (interleukin and matrix 
metalloproteinases for example). The aggregation of platelets results in the formation of a platelet 
clot, a fibrin scaffold that allows for cellular migration into the injury and retains the growth factors 
at the injury site. (Foster et al., 2009).  
PRP can be prepared either by centrifugation or filtration by gravity of the autologous blood 
(platelets are smaller and less dense than erythrocytes and leukocytes), but it is highly variable 
between individuals and preparatory techniques. There are several commercial systems, so there 
will be important variations between the different preparations, whether in platelet and leukocyte 
concentration, whether in fibrin architecture. Some authors believe that leukocyte poor PRP is 
preferential, as white blood cells may induce further inflammation through the release of 
inflammatory cytokines (Fortier, 2010).  
 
PRP has advantages in its ease of use, the fact that it administrates autologous peptides 
(diminishing the risk for immune reactions), along with a combination of growth factors that help 
the natural healing process, and it has a low cost when compared to stem cells (Ortved, 2018).  
The disadvantages of PRP lye with the lack of stem cells within the preparations, and the 
variability between the various products that are available, both in platelet concentration and 
residual leukocyte content (Fortier, 2010; Middleton et al., 2012).  
 
Platelet concentrations are positively correlated with growth factor concentrations, as well as with 
tendon and ligament matrix gene expression. More platelets, more growth factors, more 
extracellular matrix expression, more collagen type one cartilageoligomeric matrixprotein.  
More white blood cells mean more collagen type three, associated with scar tissue (Ortved, 2018). 
 
The optimal time for PRP treatment after lesion development has yet to be determined, but it has 





PRP, due to the anti-inflammatory factors present in the solution (Ortved, 2018). It has been 
shown that tendons treated with PRP seven days after SDFT lesion onset, had earlier 
improvement of ultrasonographic parameters, than tendons treated 14 days after injury (Fonseca 
et al., 2014). 
3.2 Mesenchymal stem cells 
3.2.1 Historical perspective 
In the 1890’s scientists proposed the existence of a cell which originated in the bone marrow and 
migrated along the blood stream, to injury sites across the organism, in order to participate in the 
tissue regeneration (Bianco, 2009). This was the first time a concept of mesenchymal stem cells 
was introduced, but only in the 1970s the first breakthrough was made in this field, as Friedenstein 
cultured bone forming cells from guinea-pigs (Friedenstein et al., 1970), characterising them 
subsequently as a minor subpopulation of marrow derived plastic-adherent cells, with osteogenic, 
chondrogenic and hematopoietic supportive potential (Friedenstein et al., 1974), challenging the 
previous theories that assumed a hematopoietic origin of these cells. Subsequent studies 
established that these cells could be isolated by plastic adherence, and that they could form 
osteoblasts, chondrocytes, adipocytes and myoblasts ( Friedenstein et al., 1987; Owen et al., 
1988; Piersma et al., 1985). In 1992 the first isolation and culture of human MSCs was reported 
by Caplan and Haynesworth (Haynesworth et al., 1992), who eventually went on to implant these 
cells in humans in 1993 (Lazarus et al., 1995). Arnold Caplan was also the one who introduced 
the term “mesenchymal stem cells”, comparing these cells with the stem cells who originate from 
the mesodermal tissues of the embryo (Caplan, 1991). Later in the 90’s the ligands of the SH-2 
and SH-3 antibodies were described as CD105 and CD73 respectively (Barry et al., 2001; Barry 
et al., 1999).  
From here on it became possible to characterize MSCs according to their ability to adhere to 
plastic, the expression of cell surface markers, and their capacity to give rise to mesodermal cell 
lineages in vitro.  
These were the pioneers of the field of MSCs, soon to be followed by equally important pioneers 
of equine MSCs. Fortier and her team were able to isolate and cultivate for the first time equine 
bone stem cells from bone marrow aspirate, in 1998 (Fortier et al., 1998). And in 2003 Smith was 
able to implant autologous, in vitro expanded, bone marrow MSCs, into a damaged SDFT (Smith 
et al., 2003), laying the foundation for the future of this regenerative therapy in equine medicine. 
3.2.2 Definition  
Stem cells are commonly defined as being undifferentiated cells that are able to self-renew and 
differentiate into different cell types (Ortved, 2018), as illustrated by the mesogenic process. 
Mesenchymal stem cells (MSCs) specifically are multipotent cells that originate in the mesoderm 
(Ortved, 2018). In order to have an uniform concept of mesenchymal stem cells, the International 





recognisable: 1) adherence to plastic 2) specific surface antigen expression 3) multipotent 
differentiation potential (Dominici et al., 2006).  
These definitions imply that the cells that are used in regenerative medicine are able to 
differentiate into the predominant cell type of the injured tissue (Caplan, 2017), but this is not the 
true action of the infused cells in the lesions. Instead they act as carriers of paracrine factors that 
have an immunomodulatory effect (Bruno et al., 2015). As such, there have been advocates to 
change the name of Mesenchymal Stem Cells, into Medical Signalling Cells, or Mesenchymal 
Stromal Cells (Horwitz et al., 2005; Caplan, 2017), maintaining the MSC acronym, but eliminating 
the term “stem”, that induced an erroneous thought about the properties of these cells.  
3.2.3 Mechanisms of action  
The original though behind the 
therapeutic effect of MSCs was that 
these cells would directly replace the 
damaged tissues by differentiating into 
the predominant cell type at the injury 
site and multiplying subsequently. It is 
now known that this is not the main 
therapeutic effect of MSCs (Caplan, 
2017; Ortved, 2018). The infused cells 
exert an immunomodulatory effect at 
the injury site, through paracrine 
action (Ortved, 2018). This paracrine 
action is carried out by a group of molecules and factors that MSCs secrete, called “the 
secretome” (Al Naem et al., 2019). The secretome is composed of growth factors, cytokines, 
soluble proteins, free nucleic acid, lipids, and extracellular vesicles (Al Naem et al., 2019). The 
growth factors include transforming growth factor beta (TGF-beta), hepatocyte growth factor 
(HGF), prostaglandin E2 (PGE2), interleukin 10, interleukin one receptor antagonist, interleukin 
six, human leukocyte antigen G, leukocyte inhibitory factor, indoleamine two, three-dioxygenase, 
nitric oxide, galectines one and nine, tumour necrotic factor alpha stimulated gene six (Pittenger 
et al., 2019) (Figure 7). The extracellular vesicles are made up of a lipidic bilayer, that encloses 
various cytoplasmic components, like regulatory miRNA, DNA, structural and functional proteins, 
cytokines, growth factors and signalling lipids (Bruno et al., 2015; Al Naem et al., 2019). All these 
secreted factors have individual effects on the immune answer of the host, but the synergistic 
action makes the immunomodulation completer and more effective (Ortved, 2018). 
There is a differential effect on the maturing immune cell populations that are present at the injury 
site. The natural killer cells, the dentritic DC1 cells and the proinflammatory TH1 cells are 
inhibited, while the dentritic DC2 cells, the anti-inflammatory TH2 cells and the regulatory T cells 
are upregulated (Bruno et al., 2015; Pittenger et al., 2019).  





The anti-proliferative action of MSCs is dependent on cell-to-cell contact, secreted factors and 
the factors that are carried by the extracellular vesicles, as this is the way MSCs communicate 
with neighboring cells (Bruno et al., 2015; Al Naem et al., 2019).  
Whatever the origin of the stem cells is, they always have an important role in the maintenance 
of cellular homeostasis, as well as in tissue regeneration. This is the basis of the therapeutic effect 
of MSCs (Al Naem et al., 2019). MSCs promote normal healing instead of scarring (Carrade et 
al., 2012).  
It has been suggested that MSCs may differentiate into two different types, according to the 
environment they are exposed to. Toll-like receptor three (TLR3) priming would induce the 
differentiation into an anti-inflammatory phenotype (MSC type two), while TLR4 priming conditions 
would shift MSCs into a pro-
inflammatory phenotype (MSC 
type1). MSC type one would then 
activate the innate and adaptive 
immune system elements (eg. 
M1 macrophages and T 
lymphocytes), and type two 
MSCs would promote 
immunomodulatory and trophic 
activities after the activation of 
M2 macrophages and secretion 
of specific mediators. This means 
that type one MSCs may 
contribute to the first reparative 
action against tissue injury, and 
type two MSCs contribute in a 
later phase through a 
regenerative response (Somoza 
et al., 2015) (Figure 8). 
Another interesting in vitro finding showed that inflammation causes downregulation of stem cell 
migration related genes and increases gene expression of cellular adhesion. This may explain 
the propensity of MSCs to localise to sites of inflammation (Barrachina et al., 2016).  
3.2.4 Sources 
MSCs can be isolated from virtually every vascularized tissue, due to their close relationship to 
pericytes (Esteves et al., 2017; Pittenger et al., 2019; Gomez-Salazar et al., 2020). In fact, there 
are studies that have showed a correlation between stem cell yields and vascular density in 
adipose tissue (Da Silva Meirelles et al., 2009). At the moment, various tissues from the equine 
Figure 8 - MSC secreted factors and mechanism of action in vivo 





organism have been used to isolate MSCs: bone marrow, adipose tissue (Romero et al., 2017; 
Vidal et al., 2012), embryonic tissue (Guest et al., 2010), synovial fluid and membrane, umbilical 
cord (Carrade et al., 2011), peripheral blood (Carvalho et al., 2013), periosteum, muscle (Radtke 
et al., 2013), dental pulp, periodontal ligament (Mensing et al., 2011), endometrium (Rink et al., 
2017), and even hair follicles (Michler et al., 2017) (Figure 9).   
The main sources that have been clinically used to harvest MSCs have been bone marrow and 
adipose tissue. These options will be explored in detail in the following paragraphs.  
3.2.4.1 Bone marrow 
derived MSCs  
The cancellous portions of 
bones contain bone marrow, 
a semi-solid tissue that gives 
origin to a population of 
stromal, fibroblast like, cells. 
A subpopulation of these 
cells, the MSCs, can be found 
on the endosteal surface of 
the marrow space (Alves et 
al., 2011; Stewart et al.., 
2011). The MSCs found within 
bone marrow can be harvested 
through aspiration from the tuber coxae or the sternum (Arnhold et al., 2007; Goodrich et al., 
2008; Kasashima et al., 2011). Usually the first 5ml of the aspirate contain the most MSCs, but in 
practice 10 to 20ml are collected (Kasashima et al., 2011; Stewart et al., 2011).  
The sample is collected into a heparinized container (Alves et al., 2011), and isolated in the 
laboratory. There are various isolation procedures for BM-MSCs, but the most convenient are the 
ones that are based on the plastic adherence characteristics of MSCs. With this protocol, the 
fraction of the BM aspirate, rich in mononuclear cells, is placed on plastic culture dishes and left 
to adhere for five days. When the five days are over, the cells that did not adhere, mostly 
hematopoietic cells, are discarded. The adherent cells that remain are further cultured for 14 days, 
after which they are detached through trypsinization (Al Naem et al., 2019; Stewart et al., 2011). 
Another method of isolation of BM-MSCs uses density-gradient centrifugation to separate initially 
the mononuclear cells from the hematopoietic cells. This is achieved using a Ficoll-gradient 
emulsification of the bone marrow sample. The mononuclear cell fraction is cultured afterwards 
at low densities, allowing the plastic adherent cells to form colonies, after two to three weeks, that 
derive from MSCs in a ratio of 1:1 (Pacini et al., 2007; Schnabel et al., 2014). Another density-
gradient centrifugation method uses a Percoll colloidal solution that consists of silica particles 
(Bourzac et al., 2010). The Ficoll method has a significant downside however, as it depletes highly 
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regenerative cells and impairs cell function, as it decreases the expression of chemokine 
receptors (Pösel et al., 2012). Beside this downside, density gradient centrifugation is also a 
lengthy procedure, that only allows for the recovery of 15 to 30% of the initial stem cell population 
(Al Naem et al., 2019).  
If the cultured cells are for autologous use, they are shipped back to the veterinarian after 
isolation (3 weeks), usually at a concentration of about 10 x 106 cells, or 50 x 106 when the 
defect is very large. The cells may be suspended in citrated bone marrow supernatant in order 
to supplement the MSCs with the growth factors present in the supernatant (Alves et al., 2011). 
3.2.4.2 Adipose tissue derived MSCs 
Adipose tissue originates in the mesoderm, 
contains adipocytes and a fraction of stromal cells 
that include vascular smooth muscle cells, 
endothelial cells, fibroblasts, monocytes, 
macrophages, pre-adipocyte lymphocyte and AD-
MSCs (Miana et al., 2018). These last cells, the AD-
MSCs appear to be almost indistinguishable from 
BM-MSCs, are easier to collect, and have high initial 
cell yields, making them a good alternative for BM-
MSCs, although some studies have shown that they 
do not differentiate so well into specific cell lineages 
(Vidal et al., 2007; Toupadakis et al., 2010; Alves et 
al., 2011). The most important argument to support 
this, is the fact that they show an inferior capacity to 
generate osseous or cartilaginous tissues when 
compared to BM-MSCs or other MSCs (Stewart et 
al., 2011). This lack of differentiation capacity may 
be compensated by the potent immunomodulatory 
effects that these cells appear to have, as 
demonstrated in studies with immune mediated 
arthritis (Gonzalez-Rey et al., 2010) and in vitro 
lymphocyte activation assays (Bochev et al., 2008).  
Samples may be collected from various sites, (Alves 
et al., 2011), but the most used areas are the head 
of the tail and supragluteal region (Al Naem et al., 
2019). Usually five to 10ml of adipose tissue is 
collected (Alves et al., 2011), this sample is then digested using a enzymatic collagenase solution, 
over three to 18h, depending on the needs (Al Naem et al., 2019). After this, the mononuclear cell 
fraction is separated and concentrated, being available for direct administration or to be further 
Figure 10 - The process of MSC therapy 





cultured. If they are further cultured and expanded a similar process to the one used with BM-
MSCs is applied (Alves et al., 2011) (Figure 10). If the cells are directly administered to the patient 
without further culture they are referred to as the stromal vascular fraction (SVF). They are not 
pure MSCs, instead it is a mixed population composed of endothelial cells, preadipocytes and 
MSCs (Vidal et al., 2007).  
3.2.5 Autologous vs Allogenic  
Initially MSC therapies used mainly autologous cells. However, this approach entailed several 
disadvantages such as the time frame between the diagnosis of the lesion, harvesting the cells 
and finally administrating the MSCs. It normally takes up to three weeks to culture and expand 
the cells in the laboratory, which is not ideal in a great deal of cases. Besides this big 
disadvantage, it has been shown that age and health of the donor horse influences the beneficial 
properties of the MSCs. So, an allogenic donor might provide better quality MSCs when compared 
to the autologous MSCs. Donors of younger ages appear to have cells with the best healing 
properties like an increased proliferative activity, a better differentiation ability and a different gene 
expression when compared to donors of an older age (Colbath et al., 2020; Khong et al., 2019; 
Myneni et al., 2019). Keeping in mind all the aforementioned, there has been an increasing 
interest towards allogenic MSCs, an “off the shelf” product, that can be administered right at the 
time of the diagnosis of the lesion. The MSCs with an allogenic donor also have the advantage 
to be further cultured and expanded beyond the three week time frame, making it possible to 
obtain well characterised cell lines, which allows for a more predictive outcome, as the 
administered cells are from a more uniform population (Colbath et al., 2020).  
The main concern with respect to allogenic MSCs is the safety of their repetitive administration. 
Introducing biological material derived from a different individual always poses a risk for 
immunological reactions to foreign MHC antigens (Colbath et al., 2020). To address this issue 
several studies have been performed. In vitro studies, using mixed leucocyte reactions, showed 
a significant decrease in lymphocyte proliferation (Carrade et al., 2012; Colbath et al., 2017; Holt 
et al., 2014; Paterson et al., 2014), no difference in immune suppressive ability between allogenic 
and autologous MSCs (Colbath et al., 2017), and BM-MSCs of a mismatched haplotype were 
able to significantly reduce lymphocyte proliferation (Ranera et al., 2016). In vivo studies are less 
abundant but showed positive results. When administrated intravenously and subcutaneously 
there was little evidence for adverse reactions (Kol et al., 2015;Williams et al., 2016), and the 
same occurred when allogenic MSCs where administrated intratendinously in healthy tendons 
(Guest et al., 2008; Souza et al., 2018). (Guest et al., 2008; Souza et al., 2018). 
The reduced evidence for immune responses to allogenic MSCs may be related to the inherent 
immune suppressive characteristics and low level of MHC expression by MSCs (Barberini et al., 





3.2.6 Administration  
MSCs for treatment of tendinoligamentous lesions are ideally administerd intratendinously, within 
the lesion itself if it is a contained lesion. Frequently the injection is done blindly, but the best 
result is obtained when ultrasonographic guidance is used. The horse should be sedated, and 
local analgesia applied, the area should be aseptically prepared as well (Kümmerle et al., 2019). 
It is important to use a large gauge needle to minimize damage to the cells that are administrated, 
preferably with a needle gauge above 20G (Garvican et al., 2014; Lang et al., 2017). Intralesional 
therapy should not be started before three days after lesion onset, because of risk for increasing 
the haemorrhage. Large volumes should be avoided as they can be damaging to the healing of 
the tendon (van den Belt et al., 1993).  The most common concentration for administration is 10 
x 106 cells, although this isn’t a consensual dosing (Ortved, 2018), in fact, there is yet to be 
determined a consensual dosing of MSCs in the treatment of tendinoligamentous lesions. An 
optimal timing for MSCs therapy is also yet to be determined. Some authors have the opinion that 
the administration of MSCs could be done right at the inflammatory stage, as the MSCs have 
immunomodulatory effects, reducing inflammation and stimulating local stem cells and tenoblasts 
(Docheva et al., 2015).  
4  Objective of the study   
An increasing clinical interest is developing around regenerative therapies in equine practice, 
especially around mesenchymal stem cell therapies. The most common use of MSCs in equine 
practice is the treatment of tendon injuries (Koch et al., 2019). Studies regarding the use of MSCs 
in equine tendinopathy and desmitis indicate that this regenerative therapy has a positive effect 
on this type of injuries. A study made in 2008 noted histologic improvement of tendon structure 
and cellular composition after the administration of AD-MSCs on collagenase induced tendonitis 
(Nixon et al., 2008). Studies that used bone-marrow derived mesenchymal stem cells also had 
good results. In a small study of 11 horses with naturally occurring SDF tendinopathy, 9 recovered 
completely and returned to competition, through the treatment with BM-MSCs (Pacini et al., 2007). 
While another study regarding similar lesions, that were treated with BM-MSCs as well, 
demonstrated a re-injury rate of 27,4% (Godwin et al., 2012). A larger study, that encompassed 
various tendon and ligament disorders, including SDF tendinopathy and SL desmitis, and used 
allogenic equine mesenchymal stem cells derived from umbilical cord blood, observed that 77% 
of the treated horses returned to work (Van Loon et al., 2014). And another study with allogenic 
AD-MSCs in combination with PRP, used to treat 19 horses affected by SDF tendinopathy, 
observed that 24 months post-treatment 89,5% of the horses returned to their previous level of 
competition, and 10,5% had re-injury (Ricco et al., 2013). 
This study tries to show the efficiency of MSCs for this type of injuries, comparing two different 
cell sources. It also tries to show in which conditions stem cells are best used, relative to structure, 





studies that were done regarding this subject, hopefully contributing to a better understanding of 
this novel treatment.  
5 Material and methods 
5.1 Study population  
The study population was obtained through the analysis and retrieval of cases treated with 
mesenchymal stem cells at “Dierenkliniek Wolvega” (DKW). These clinical cases were obtained 
through the veterinary management software (Animana®). From all 209 cases collected the ones 
chosen for the present study complied to the following criteria: SDFT or SL lesions, with no other 
lesions present at the moment of treatment; lesions treated solely with SVF+PRP or BM-MSCs; 
sufficient information available on Animana®.  
The information recorded encompassed: gender, age, discipline, affected structure, limb, lesion, 
chronicity of the lesion, other treatments, type of MSCs used, lameness at zero, six and 12 
months, ultrasonographic examination at zero, six and 12 months, if there was re-injury at six or 
12 months, and work level after 12 months. The information that was not possible to be retrieved 
through clinical information that was available was collected through telephonic enquiry and 
enquiry of the treating veterinarians.  
Lameness 
Lameness was evaluated according to the AAEP lameness scale (0-5): grade 0 – sound horse 
with no lameness perceptible; grade 1 – the horse shows an inconsistent and difficult to observe 
lameness, independent of the circumstances; grade 2 – lameness continues to be difficult to 
detect at walk and trot in a straight line, but becomes more apparent under certain circumstances, 
like trotting in a circle, inclines, etc; grade 3 – the horse shows lameness consistently at a trot, in 
all circumstances; grade 4 – the horse is visibly lame at a walk; grade 5 – the horse has minimal 
weight bearing on the affected limb (Baxter et al., 2020). The evaluation of the lameness was 
made by the treating veterinarians at the moment of diagnosis (zero months), six months after 
treatment and 12 months after treatment.  
Lesion category  
Ultrasonographic evaluations from each horse were retrospectively obtained from the records of 
each veterinarian. These observations were categorized in a scaled based on the 
ultrasonographic score described by Rantanen (Rantanen et al., 2010). This score was modified, 
and it was determined that scores from one to three were clinically irrelevant, while scores from 
four to six were clinically relevant. Reducing the categories from six to two was useful to simplify 
the statistical analysis and making an easier appreciation of the clinical evolution of the patients.  
 
 
